Symbiotec Pharma

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE899I01028
  • NSEID: SYMBIOTEC
  • BSEID: 544889
INR
1,598.75
-3.9 (-0.24%)
BSENSE

Nov 20

BSE+NSE Vol: 20533

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

20.53 k (-16.82%) Volume

Shareholding (Sep 2026)

FII

3.79%

Held by 23 FIIs

DII

33.17%

Held by 21 DIIs

Promoter

33.28%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 10,485 Cr (Mid Cap)

stock-summary
P/E

92.00

stock-summary
Industry P/E

40

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.12

stock-summary
Return on Equity

10.48%

stock-summary
Price to Book

6.91

Revenue and Profits:
Net Sales:
280 Cr
(Quarterly Results - Sep 2026)
Net Profit:
52 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Icon
Company does not have enough history
Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary

Intimation Regarding Change In Corporate Identification Number (CIN) And Listing Status Of The Company.

17-Nov-2026 | Source : BSE

Intimation regarding change in Corporate Identification Number (CIN) and Listing Status of the Company.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

12-Nov-2026 | Source : BSE

Pursuant to Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended from time to time we would like to inform you that the officials of the Company will be attending an Investor

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

12-Nov-2026 | Source : BSE

Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
8.46
Debt to EBITDA (avg)
0.85
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
0.73
Tax Ratio
33.07%
Dividend Payout Ratio
0
Pledged Shares
38.54%
Institutional Holding
36.96%
ROCE (avg)
14.20%
ROE (avg)
17.21%
Valuation key factors
Factor
Value
P/E Ratio
92
Industry P/E
40
Price to Book Value
6.91
EV to EBIT
52.23
EV to EBITDA
43.68
EV to Capital Employed
6.29
EV to Sales
12.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
12.03%
ROE (Latest)
10.48%
Technicals key factors
Indicator
Weekly
Monthly
MACD
RSI
Bollinger Bands
KST
Dow Theory
Bullish
OBV
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

38.5416

Mutual Funds

Held by 13 Schemes (12.18%)

FIIs

Held by 23 FIIs (3.79%)

Promoter with highest holding

Satwani Holdings Llp (15.28%)

Highest Public shareholder

Rosewood Investments (14.07%)

Individual Investors Holdings

7.81%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Sep'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2026 is 4.35% vs -1.05% in Jun 2026",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2026 is 3.25% vs 399.62% in Jun 2026",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'26",
        "Jun'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "220.02",
          "val2": "210.84",
          "chgp": "4.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "59.98",
          "val2": "59.24",
          "chgp": "1.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.97",
          "val2": "5.62",
          "chgp": "-11.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "48.54",
          "val2": "47.01",
          "chgp": "3.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.26%",
          "val2": "28.10%",
          "chgp": "-0.84%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Symbiotec Pharma"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Symbiotec Pharma"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "845.17",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "240.64",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "23.80",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-61.13",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "115.83",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "28.47%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Sep'26 - QoQstock-summary
Sep'26
Jun'26
Change(%)
Net Sales
220.02
210.84
4.35%
Operating Profit (PBDIT) excl Other Income
59.98
59.24
1.25%
Interest
4.97
5.62
-11.57%
Exceptional Items
0.00
0.00
Standalone Net Profit
48.54
47.01
3.25%
Operating Profit Margin (Excl OI)
27.26%
28.10%
-0.84%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2026 is 4.35% vs -1.05% in Jun 2026

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Sep 2026 is 3.25% vs 399.62% in Jun 2026

Annual Results Snapshot (Standalone) - Mar'26stock-summary
Mar'26
Change(%)
Net Sales
845.17
NA
NA
Operating Profit (PBDIT) excl Other Income
240.64
NA
NA
Interest
23.80
NA
NA
Exceptional Items
-61.13
NA
NA
Standalone Net Profit
115.83
NA
NA
Operating Profit Margin (Excl OI)
28.47%
NA%
NA
Values in Rs Cr.
Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

stock-summaryCompany CV
About stock-summary
stock-summary
Company Coordinates stock-summary
Company Details
stock-summary
Tel:
stock-summary
stock-summary
Registrar Details